KR101710981B1 - 개선된 백신 및 이의 사용 방법 - Google Patents

개선된 백신 및 이의 사용 방법 Download PDF

Info

Publication number
KR101710981B1
KR101710981B1 KR1020167007633A KR20167007633A KR101710981B1 KR 101710981 B1 KR101710981 B1 KR 101710981B1 KR 1020167007633 A KR1020167007633 A KR 1020167007633A KR 20167007633 A KR20167007633 A KR 20167007633A KR 101710981 B1 KR101710981 B1 KR 101710981B1
Authority
KR
South Korea
Prior art keywords
seq
nucleotides
less
amino acids
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167007633A
Other languages
English (en)
Korean (ko)
Other versions
KR20160038075A (ko
Inventor
데이비드 비. 웨이너
지안 얀
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20160038075A publication Critical patent/KR20160038075A/ko
Application granted granted Critical
Publication of KR101710981B1 publication Critical patent/KR101710981B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167007633A 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법 Active KR101710981B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83386106P 2006-07-28 2006-07-28
US83385606P 2006-07-28 2006-07-28
US60/833,856 2006-07-28
US60/833,861 2006-07-28
US89035207P 2007-02-16 2007-02-16
US60/890,352 2007-02-16
PCT/US2007/074769 WO2008014521A2 (en) 2006-07-28 2007-07-30 Improved vaccines and methods for using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035344A Division KR101609235B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004941A Division KR101848867B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20160038075A KR20160038075A (ko) 2016-04-06
KR101710981B1 true KR101710981B1 (ko) 2017-02-28

Family

ID=38982433

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020167007633A Active KR101710981B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020207031173A Active KR102334637B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020147035344A Active KR101609235B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020097004232A Active KR101562888B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020247035070A Ceased KR20240159010A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020177004941A Active KR101848867B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020217039157A Active KR102511874B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020187010028A Active KR101999376B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020197019662A Active KR102173636B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020237009029A Ceased KR20230042399A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Family Applications After (9)

Application Number Title Priority Date Filing Date
KR1020207031173A Active KR102334637B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020147035344A Active KR101609235B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020097004232A Active KR101562888B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020247035070A Ceased KR20240159010A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020177004941A Active KR101848867B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020217039157A Active KR102511874B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020187010028A Active KR101999376B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020197019662A Active KR102173636B1 (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법
KR1020237009029A Ceased KR20230042399A (ko) 2006-07-28 2007-07-30 개선된 백신 및 이의 사용 방법

Country Status (12)

Country Link
US (4) US8168769B2 (enExample)
EP (7) EP4400510A3 (enExample)
JP (9) JP2009544333A (enExample)
KR (10) KR101710981B1 (enExample)
CN (3) CN105063064B (enExample)
AU (3) AU2007278831B2 (enExample)
CA (4) CA3057039C (enExample)
DK (2) DK3037429T3 (enExample)
ES (2) ES2589013T3 (enExample)
HK (1) HK1218427A1 (enExample)
MX (3) MX346862B (enExample)
WO (1) WO2008014521A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
WO2010101946A1 (en) 2009-03-02 2010-09-10 The Regents Of The University Of California DEVICES GROWN ON NONPOLAR OR SEMIPOLAR (Ga,Al,In,B)N SUBSTRATES
WO2011032179A1 (en) * 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011097640A1 (en) * 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
US9657068B2 (en) 2010-02-16 2017-05-23 Ultimovacs As Telomerase polypeptide vaccine for treating cancer
US8932575B2 (en) 2010-09-21 2015-01-13 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
CA2814386C (en) * 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
EP2750703B1 (en) * 2011-10-12 2018-07-04 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
AU2012352455B2 (en) * 2011-12-12 2016-01-21 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
EP2892913A4 (en) * 2012-09-07 2017-01-18 Agency For Science, Technology And Research Peptides and their uses
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
KR20220140025A (ko) 2013-03-12 2022-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파밀로마 바이러스용 개선된 백신 및 이것을 사용하는 방법
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
KR102395493B1 (ko) * 2013-11-14 2022-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Hiv-1 env dna 백신과 단백질 부스터
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
KR20240132103A (ko) * 2015-01-29 2024-09-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
AU2017214656B2 (en) * 2016-02-05 2022-08-25 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
CN109069575A (zh) * 2016-02-23 2018-12-21 毛里齐奥·扎内蒂 通用癌症疫苗
US11464841B2 (en) * 2016-09-30 2022-10-11 The Trustees Of The University Of Pennsylvania TERT immunogenic compositions and methods of treatment using the same
US20190076460A1 (en) * 2017-02-22 2019-03-14 Enyu Ding An mRNA cancer vaccine encoding human GM-CSF fused to multiple tandem epitopes
CN109142723B (zh) * 2018-08-21 2021-07-13 苏州华益美生物科技有限公司 人类免疫缺陷病毒快速检测测试卡及其应用
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US2579A (en) 1842-04-21 Flour-ing-mill combining a smut-machine with the scouring-stones
US2157994A (en) 1937-11-08 1939-05-09 Kelsey Hayes Wheel Co Brake mechanism
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
KR100252371B1 (ko) * 1990-12-12 2000-05-01 포터 더글라스 서브유니트 파필로마비루스 백신 및 그들에 사용하기 위한 펩티드
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
PT681483E (pt) 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
NZ267838A (en) 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US5703655A (en) 1995-03-24 1997-12-30 U S West Technologies, Inc. Video programming retrieval using extracted closed caption data which has been partitioned and stored to facilitate a search and retrieval process
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US7585622B1 (en) * 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
CN1240480A (zh) * 1996-10-18 2000-01-05 坎吉有限公司 运送和表达干扰素－α核酸的方法和组合物
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE19720914A1 (de) * 1997-05-16 1998-11-19 Boehringer Mannheim Gmbh Verfahren zum Nachweis von HIV-Antikörpern und dazu verwendete Antigene
CA2294782A1 (en) * 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DK2044950T3 (da) 1997-09-18 2012-09-17 Univ Pennsylvania Svækkede VIF-DNA-immuniseringskassetter til genetiske vacciner
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CN1312171C (zh) 2000-07-14 2007-04-25 宾夕法尼亚州立大学托管会 可编码hiv辅助蛋白的dna疫苗
CA2424216A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
EP1195438A1 (en) 2000-10-06 2002-04-10 Rijksuniversiteit te Groningen Genetic immunisation against cervical carcinoma
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
CN1468956A (zh) * 2002-07-15 2004-01-21 杨 琴 高效表达治疗肿瘤的抗体的重组病毒及其用途
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
WO2004037175A2 (en) 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
CN1453361A (zh) * 2003-05-30 2003-11-05 中国科学院上海生命科学研究院 一种抗癌靶向可调控基因－病毒的构建方法
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
JP4773352B2 (ja) * 2003-09-17 2011-09-14 デューク ユニバーシティ コンセンサス／先祖免疫原
US20070275010A1 (en) * 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
WO2005060993A1 (en) * 2003-12-24 2005-07-07 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2005108564A2 (en) * 2004-03-25 2005-11-17 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusion
CN1775802A (zh) * 2004-11-17 2006-05-24 宋硕 人类乳头瘤病毒免疫原性多肽、其制备方法及应用
WO2006119516A2 (en) * 2005-04-29 2006-11-09 University Of Cape Town Expression of viral proteins in plants
MX2008000890A (es) * 2005-07-19 2008-03-18 Dow Global Technologies Inc Vacunas de influenza (flu) recombinantes.
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gao. F., et al. J Virol 2005. 79:1154-63

Also Published As

Publication number Publication date
JP2015012874A (ja) 2015-01-22
CA3057039A1 (en) 2008-01-31
JP2013081482A (ja) 2013-05-09
EP2594576A1 (en) 2013-05-22
EP2049559A4 (en) 2011-03-02
ES2589013T3 (es) 2016-11-08
JP2022081665A (ja) 2022-05-31
JP6186333B2 (ja) 2017-08-23
EP3489251B1 (en) 2021-03-17
KR20150003921A (ko) 2015-01-09
CA3057039C (en) 2023-02-28
AU2013201592B2 (en) 2015-03-12
US20130004529A1 (en) 2013-01-03
CA2949851A1 (en) 2008-01-31
MX346862B (es) 2017-04-04
WO2008014521A2 (en) 2008-01-31
EP3907232A1 (en) 2021-11-10
EP2708549A3 (en) 2014-05-21
DK2049559T3 (da) 2013-03-25
KR102173636B1 (ko) 2020-11-04
EP2049559A2 (en) 2009-04-22
EP3907232B1 (en) 2024-02-21
EP3489251A1 (en) 2019-05-29
EP4400510A3 (en) 2025-03-05
CN105132439A (zh) 2015-12-09
CA2659262C (en) 2017-01-10
US8168769B2 (en) 2012-05-01
CA2949851C (en) 2019-11-12
US9290546B2 (en) 2016-03-22
CN101679475A (zh) 2010-03-24
KR101609235B1 (ko) 2016-04-05
AU2007278831A1 (en) 2008-01-31
AU2024200014A1 (en) 2024-03-14
JP2020103317A (ja) 2020-07-09
MX2009001099A (es) 2009-02-10
ES2706501T3 (es) 2019-03-29
EP2708549B1 (en) 2016-07-06
KR20190083680A (ko) 2019-07-12
KR20170024131A (ko) 2017-03-06
KR101999376B1 (ko) 2019-07-11
CN101679475B (zh) 2015-08-12
AU2024200014B2 (en) 2025-11-27
EP4400510A2 (en) 2024-07-17
JP2018108110A (ja) 2018-07-12
JP2009544333A (ja) 2009-12-17
KR101848867B1 (ko) 2018-04-13
US20100166787A1 (en) 2010-07-01
EP2594576B1 (en) 2015-07-01
JP2016029105A (ja) 2016-03-03
EP2049559B1 (en) 2012-12-19
JP2020103318A (ja) 2020-07-09
CA2659262A1 (en) 2008-01-31
MX340880B (es) 2016-07-28
CN105063064A (zh) 2015-11-18
EP3037429A1 (en) 2016-06-29
EP2708549A2 (en) 2014-03-19
KR101562888B1 (ko) 2015-10-26
WO2008014521A8 (en) 2012-06-14
KR20210151987A (ko) 2021-12-14
KR102511874B1 (ko) 2023-03-20
WO2008014521A3 (en) 2008-12-24
JP6097086B2 (ja) 2017-03-15
KR20240159010A (ko) 2024-11-05
HK1218427A1 (zh) 2017-02-17
EP3037429B1 (en) 2018-09-26
DK3037429T3 (en) 2019-01-21
CA3184778A1 (en) 2008-01-31
AU2007278831B2 (en) 2013-03-21
US9376471B2 (en) 2016-06-28
KR20230042399A (ko) 2023-03-28
CN105063064B (zh) 2024-09-24
KR20160038075A (ko) 2016-04-06
KR20200126024A (ko) 2020-11-05
KR102334637B1 (ko) 2021-12-06
KR20180041247A (ko) 2018-04-23
US8697084B2 (en) 2014-04-15
JP7030347B2 (ja) 2022-03-07
US20140186384A1 (en) 2014-07-03
JP2025032154A (ja) 2025-03-11
US20140341941A1 (en) 2014-11-20
KR20090046899A (ko) 2009-05-11
HK1130807A1 (en) 2010-01-08
JP6356653B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
KR101710981B1 (ko) 개선된 백신 및 이의 사용 방법
AU2021204612B2 (en) Improved vaccines and methods for using the same
HK40114241A (en) Improved vaccines and methods for using the same
HK40064045B (en) Improved hiv vaccines
HK40064045A (en) Improved hiv vaccines

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160323

Application number text: 1020147035344

Filing date: 20141216

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160518

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20161121

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170222

Application number text: 1020147035344

Filing date: 20141216

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200206

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200206

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210209

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220215

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240206

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20250106

Start annual number: 9

End annual number: 9